Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment Patterns And Clinical Outcomes Among Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (mBC) Receiving Palbociclib in Combination With Fulvestrant (PB+FUL) In The US Community Oncology Setting

Next Previous
Trial Profile

Treatment Patterns And Clinical Outcomes Among Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (mBC) Receiving Palbociclib in Combination With Fulvestrant (PB+FUL) In The US Community Oncology Setting

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 05 Dec 2022 Status changed from active, no longer recruiting to completed.
  • 18 Mar 2021 Treatments section is updated to decrease the number of arms from 4 to 2, by removing the cohort 1b and 2b arms completed and remaining cohort 1a and 2a have been re-designated as palbociclib-fulvestrant combination and fulvestrant monotherapy arms. The aromatase inhibitors (letrozole, exemestane, or anastrozole) are removed from the study treatments.
  • 18 Mar 2021 Planned End Date changed from 31 Mar 2022 to 30 Apr 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top